Viewpoint

Money is not the lure for expats moving back to Asia. This calls for a rethink of how to retain talent in Europe and North America, says Nuala Moran.

Prickly issues like IP and publication rights should no longer be allowed to dilute academic-industrial partnerships, writes Nuala Moran.

It’s no great revelation that the biotech funding model is broken, yet the market for the industry’s drugs has never been greater. So where is the fix, asks Nuala Moran.

The EU doesn’t do fundamental research, which is why it has taken 20 years for researchers involved in high risk research to get together, but it can’t get by without it.

As life sciences investors shy away from drug development and opt for lower-risk devices and diagnostics, what can Europe learn from Israel’s experience?

As governments direct stimulus packages towards science and research, don’t forget the current crop of spin-outs who face extinction in a frozen capital market, writes Nuala Moran.

As governments plough in $3 trillion to stimulate growth, 52 major companies and leading climate change experts argue for policies to promote low carbon technology.

Bring on the science superstars: In an age when schoolchildren are obsessed with celebrity, they need to see science creates heroes too, writes Dave Madden.

Beyond its blockbuster drugs Genentech has a commodity rare in a large company – an entrepreneurial culture. Can Roche preserve this?

When new European Commissioners are chosen later this year, they should take the opportunity to create a Vice President for Innovation, says Richard L. Hudson.